SGLT2 抑制剂对常染色体显性多囊肾病二价离子的短期影响 (SIDIA)
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.
研究概览
详细说明
This investigator-initiated randomised, single-blind, placebo-controlled cross-over study aims to better understand tubular electrolyte handling of divalent ions in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
After randomization, at week 0, participants collect 24-hour urine sample and a patient visit to assess vitals and blood tests takes place. After this visit, period 1 starts with a 2-week treatment of either Empagliflozin 10mg or Placebo.
At week 2, the second 24-hour-urine sample and 2. patient visit and blood test take place. After this visit, wash-out period for 2 weeks starts where no study drug will be administered At week 4, the period 2, the crossover-period starts for an additional 2 weeks. At week 6; a final and third 24-hour urine sample, clinical visit and blood test takes place.
At week 3 & 7, a phone consultation will assess safety.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Canton of Zurich
-
Zurich、Canton of Zurich、瑞士、8091
- University Hospital Zurich, Division of Nephrology
-
-
Kanton Graubünden
-
Chur、Kanton Graubünden、瑞士、7000
- Cantonal Hospital Graubuenden
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- - Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan
- Informed consent as documented by signature
Exclusion Criteria:
- - renal replacement therapy or kidney allograft recipient
- chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2)
- patients younger 18 years of age
- Diabetes mellitus type 1
- recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization/year.
- Patients with uncontrolled hypertension (defined as ambulatory systolic BP over 180mmHg), liver cirrhosis (Child Pugh B and C)
- Patients not able or not willing to stop the following medications during the study period of participation in the trial:
- Thiazide diuretics
- Carbonic anhydrase inhibitors
- Sodium bicarbonate
- 1, 25 (OH) vitamin D (calcitriol)
- Bisphosphonate, denosumab, teriparatide
- Pregnant or lactating women
- Known allergy to study drug
- Inability to understand and follow the protocol
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intervention
Empagliflozin 10mg |
Empagliflozin 10mg |
|
安慰剂比较:Control
Placebo |
Placebo capsule |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
24-hour Urinary Phosphate
大体时间:End of each 14 day treatment period
|
Total phosphate excretion measured in a 24-hour urine collection at the end of each treatment period. |
End of each 14 day treatment period
|
|
24-hour Urinary Calcium Excretion
大体时间:End of each 14-day treatment period
|
Effect of empagliflozin compared with placebo on 24-hour urinary calcium excretion after each 14-day treatment period in a randomized crossover trial. |
End of each 14-day treatment period
|
|
24-hour Urinary Magnesium Excretion
大体时间:End of each 14-day treatment period
|
Effect of empagliflozin compared with placebo on 24-hour urinary magnesium excretion after each 14-day treatment period in a randomized crossover trial. |
End of each 14-day treatment period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum Phosphate
大体时间:End of each 14-day treatment period
|
Effect of empagliflozin compared with placebo on serum phosphate after each 14-day treatment period. |
End of each 14-day treatment period
|
|
Serum Calcium
大体时间:End of each 14-day treatment period
|
Effect of empagliflozin compared with placebo on serum calcium after each 14-day treatment period. |
End of each 14-day treatment period
|
|
Serum Magnesium
大体时间:End of each 14-day treatment period
|
Effect of empagliflozin compared with placebo on serum magnesium after each 14-day treatment period. |
End of each 14-day treatment period
|
|
24-hour Urine Volume
大体时间:End of each 14-day treatment period
|
Total urine volume collected over 24 hours at the end of each treatment period. |
End of each 14-day treatment period
|
合作者和调查者
调查人员
- 首席研究员:Thomas Fehr, MD、Cantonal Hospital Graubuenden
- 首席研究员:Patrick Hofmann, MD、Cantonal Hospital Graubuenden
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2024-00070
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The local ethics committee approval does not include individual participant data sharing.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.